SecurityOCLS / Oculus Innovative Sciences, Inc. (83558L105)
Institutional Owners22
Institutional Shares1,198,835 - 25.33%
Common Shares Outstanding4,732,202 shares (as of 2017-12-31)
Institutional Value$ 1,600,000 USD

Institutional Stock Ownership and Shareholders

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) has 22 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,198,835 shares. Largest shareholders include Montreux Equity Partners V, L.p., Bard Associates Inc, Vanguard Group Inc, Renaissance Technologies LLC, JW Asset Management, LLC, BlackRock Inc., Deutsche Bank Ag\, National Asset Management, Inc., Geode Capital Management, Llc, and Wade G W & Inc.

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) ownership summary shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-02-14 13F-HR MORGAN STANLEY 3,316 3,316 0.00 17 18 5.88
2018-02-08 13F-HR SEI INVESTMENTS CO 4 4 0.00 0 0
2018-02-14 13F-HR ROYAL BANK OF CANADA 7 7 0.00 0 0
2017-11-02 13F-HR/A-1 Advisor Group, Inc. 985 0 -100.00 5 0 -100.00
2018-02-09 13F-HR BlackRock Inc. 28,503 28,739 0.83 149 157 5.37
2018-01-18 13F-HR ACADIAN ASSET MANAGEMENT LLC 955 0 -100.00 5 0 -100.00
2018-02-12 13F-HR Blackhawk Capital Partners Llc. 485 3
2018-02-13 SC 13G BARD ASSOCIATES INC 334,199
2018-02-14 13F-HR UBS Group AG 1,000 4,444 344.40 5 24 380.00
2018-03-09 SC 13G Montreux Equity Partners V, L.p. 571,428
2018-02-09 13F-HR Tower Research Capital LLC (TRC) 0 0 0 0
2018-04-10 13F-HR Gradient Investments LLC 285 1
2018-02-14 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 328 3,853 1,074.70 2 21 950.00
2018-02-14 13F-HR VANGUARD GROUP INC 86,417 86,197 -0.25 451 473 4.88
2018-02-14 13F-HR DEUTSCHE BANK AG\ 0 25,141 0 137
2018-02-08 13F-HR WELLS FARGO & COMPANY/MN 1,014 1,014 0.00 5 6 20.00
2018-02-13 13F-HR WADE G W & INC 11,000 60
2018-02-13 13F-HR GEODE CAPITAL MANAGEMENT, LLC 13,177 13,177 0.00 68 72 5.88
2017-11-09 13F-HR JP Morgan Chase & Co 303 0 -100.00 2 0 -100.00
2018-04-10 13F-HR Hartford Financial Management Inc. 500 500 0.00 2 1 -50.00
2018-01-31 13F-HR Malaga Cove Capital, LLC 8,600 0 -100.00 45 0 -100.00
2018-02-14 13F-HR BANK OF AMERICA CORP /DE/ 980 540 -44.90 5 3 -40.00
2018-02-15 13F-HR National Asset Management, Inc. 10,350 14,802 43.01 53 81 52.83
2018-02-13 13F-HR Renaissance Technologies LLC 36,922 58,602 58.72 193 319 65.28
2018-02-12 13F-HR CITIGROUP INC 34 34 0.00 0 0
2018-02-12 13F-HR JW Asset Management, LLC 100,951 40,951 -59.43 527 223 -57.69
2018-04-13 13F-HR BANK OF MONTREAL /CAN/ 564 0 -100.00 3 0 -100.00

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 83558L105